Clinical Research Directory
Browse clinical research sites, groups, and studies.
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
Sponsor: GrandPharma (China) Co., Ltd.
Summary
Yttrium-90 (y90) Microsphere Injection Solution was approved by the NMPA in 2022. Currently, there is a lack of summary of real-world data in China. Therefore, this retrospective real-world study is intented to explore the characteristics and efficacy of HCC patients treated with y90 in China, aiming to provide reference for guiding and optimizing clinical practices and subsequent confirmatory clinical studies for the treatment of HCC patients in China.
Official title: A Descriptive, Retrospective, Single-Arm Cohort Study on the Use of Selective Internal Radiation Therapy (SIRT) with Yttrium-90 Microspheres for Unresectable Primary Hepatocellular Carcinoma (HCC) in the Chinese Population
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2024-08-22
Completion Date
2025-06-30
Last Updated
2024-12-05
Healthy Volunteers
No
Interventions
Yttrium-90 (Y-90) resin microspheres
selective internal radiation therapy
Locations (6)
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Jinan University
Jinan, Guangdong, China
Xi'An International Medical Center Hospital
Xi’an, Guangxi, China
No.1 Affiliated Hospital of Xian Jiaotong University
Xi’an, Shanxi, China
Beijing Tsinghua Changgung Hospital
Beijing, China
The Third Affiliated Hospital of Naval Medical University
Shanghai, China